公开(公告)号：WO2021110950A1

公开(公告)日：2021-06-10

申请号：PCT/EP2020/084701

申请日：2020-12-04

Applicant: SCIENCONS AS

Inventor： LARSEN, Roy, H.

IPC: G21G1/00 ,  A61K51/12

Abstract: The present invention relates to assemblies and method for obtaining a container comprising212Pb on the walls obtained from a212Pb precursor isotope source. The invention provides an improved system and method for producing212Pb in high purity without the need for processing, with high yields, and which safely and efficiently can be transported to the locations where it is to be used.

公开(公告)号：WO2016135200A1

公开(公告)日：2016-09-01

申请号：PCT/EP2016/053874

申请日：2016-02-24

Applicant: SCIENCONS AS

Inventor： LARSEN, Roy, Hartvig

IPC: A61K51/04 ,  A61K51/10

CPC classification number: A61K51/0474 ,  A61K51/1051

Abstract: The present invention relates to radiopharmaceutical compositions comprising the mother nuclide 224 Ra, its daughter nuclide 212 Pb, and a complexing agent that complexes with the daughter nuclide. The use of targeted chelate scavengers for 224 Ra daughter nuclide opens up the possibility for using 224 Ra based solutions for medical treatments.

Abstract translation: 本发明涉及包含母核素224Ra，其子核素212Pb和与子核素复合的络合剂的放射性药物组合物。 使用224Ra子核素的靶向螯合物清除剂开启了使用基于224Ra的解决方案进行医疗治疗的可能性。

公开(公告)号：WO2019115684A1

公开(公告)日：2019-06-20

申请号：PCT/EP2018/084738

申请日：2018-12-13

Applicant: SCIENCONS AS

Inventor： LARSEN, Roy Hartvig

IPC: A61K51/04 ,  A61P35/04 ,  A61P35/00 ,  A61K103/40 ,  A61K103/00

CPC classification number: C07F7/24 ,  A61K51/0402 ,  A61K51/0497 ,  A61P35/00 ,  A61P35/04 ,  C07B59/002 ,  C07B2200/05 ,  C07F3/003 ,  C07F9/94

Abstract: The present invention relates to complexes comprising a prostate- specific membrane antigen (PSMA) targeting compound linked to a radionuclide, such as 212 Pb or 227 Th, through a TCMC or DOTA chelating moiety. These compounds, and pharmaceutical compositions comprising them, can be used for medical applications. These applications include the treatment of prostate cancer, and the complexes allow for dual targeting of cancers.

公开(公告)号：WO2017220767A1

公开(公告)日：2017-12-28

申请号：PCT/EP2017/065508

申请日：2017-06-23

Applicant: SCIENCONS AS

Inventor： LARSEN, Roy Hartvig

IPC: A61K51/10

Abstract: The present invention relates to the generation of lead-212 for therapeutic use. Specifically, are methods related to the generation of lead-212 based radio labelled proteins, such as radioimmunoconjugates, embodiments of the present invention.

Abstract translation: 本发明涉及用于治疗用途的铅-212的产生。 具体而言，涉及与产生基于铅-212的放射性标记蛋白质如放射免疫缀合物，本发明的实施方案有关的方法。